PHASE I STUDY OF INTRAVENOUSLY ADMINISTERED ATI-1123, A LIPOSOMAL DOCETAXEL FORMULATION IN PATIENTS WITH ADVANCED SOLID TUMORS

Saturday, July 26, 2014

Read the Story Here

Related Posts

Discover more posts like this.

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

Dec 17, 2024

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Dec 17, 2024

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Dec 17, 2024
See All Posts